Use of Tofacitinib for Ulcerative Colitis in a Liver Transplant Patient - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Journal of Crohn's and Colitis Année : 2021

Use of Tofacitinib for Ulcerative Colitis in a Liver Transplant Patient

Résumé

There is a lack of consensus regarding the treatment of inflammatory bowel disease after liver transplantation [LT],1 although some LT patients have responded favourably and safely to biologic therapies such as anti-tumour necrosis factor [TNF] therapy and vedolizumab.2–4 Recently tofacitinib, an oral small molecule Janus kinase [JAK] inhibitor, was shown to have potential efficacy as induction and maintenance therapy for moderately to severely active ulcerative colitis [UC].5 However, to our knowledge, there are no published data on the safety and efficacy of using tofacitinib in the management of active UC in LT recipients.
Fichier non déposé

Dates et versions

hal-03516226 , version 1 (07-01-2022)

Identifiants

Citer

Lucy Meunier, Clémentine Clerc, Magdalena Meszaros. Use of Tofacitinib for Ulcerative Colitis in a Liver Transplant Patient. Journal of Crohn's and Colitis, 2021, 15 (4), pp.695-695. ⟨10.1093/ecco-jcc/jjaa032⟩. ⟨hal-03516226⟩

Collections

UNIV-MONTPELLIER
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More